Liana, diagnosed with hATTR amyloidosis
and her daughter Gabriella (Brazil)
>
0
%
U.S. residents with confirmed access to one of our therapies
0
countries where patients can access our therapies by way of direct or distributor infrastructure
0
+
patients supported by Alnylam Assist in 2024
Patient Services
Alnylam Assist®
Since Alnylam’s first commercial launch in 2018, our comprehensive, in-house ecosystem, Alnylam Assist®, has supported patients throughout their entire treatment journey. Alnylam Assist® is primarily staffed by Alnylam employees solely dedicated to supporting patients and providers throughout the journey with an Alnylam therapeutic. This model has enabled our team to develop a deep understanding of the patient journey so that they can expertly manage issues related to treatment initiation, access and reimbursement, and offer financial assistance to provide best-in-class patient support services.
Alnylam Act®
Alnylam Act® is a sponsored, no-charge, third-party genetic testing and counseling program for people in the U.S. and Canada with a family history or suspected diagnosis of certain genetic conditions. The Alnylam Act program was developed to provide genetic testing and counseling services to people and their families so that they may make more informed decisions about their health. Through the Alnylam Act program, genetic testing and counseling is offered at no charge to individuals who meet the eligibility criteria.
Sustainable Value and Significant Impact
We believe it is our responsibility to push the boundaries of scientific discovery, clinical development, and delivery to fuel significant, sustainable patient impact.
- We make decisions for as many people who can benefit from the potential of our medicines.
- We believe we have an obligation to commit resources that promote diversity of clinical trials, ensure equitable access, and empower individuals with choice.
- We act with purposeful urgency to expand our geographic reach and enable sustainable access pathways.
2650+
patients participating in clinical trials for our therapies
89%
of EU countries have access to at least one of our therapies
45+
countries where patients have received access to our therapies
860
patients worldwide who received access to our therapies through compassionate use to date
70
countries where patients can access our therapies by way of direct or distributor infrastructure
Connecting to Achieve Better Outcomes
We believe that together with partners in the healthcare ecosystem, we can reduce barriers to our medicines to improve outcomes for all stakeholders in the patient journey – most importantly, for the patients who may benefit from them.
- We believe biopharmaceutical companies must address access and improve outcomes from the time of drug discovery.
- We recognize that a patient’s ability to access and afford our medicines is complex, and we commit to continuing our legacy of value-centric solutions.
- We seek to remove barriers within our control to enable patients to receive care in convenient settings.
25
patient voice inclusion interviews
3,600+
personalized patient touchpoints by Patient Education Liason (PEL) team
2,000+
U.S. patients supported by in Alnylam Assist®
>50
value-based agreements signed with U.S. payers across therapies
>97%
of U.S. residents with confirmed access to our therapies across commercial, Medicare, Medicaid, and other government payer categories
$0
out of pocket
34%
of U.S. patients receiving any financial assistance or participating in access programs across all our therapies
Proactive and Accountable
We believe that biopharmaceutical companies play a critical role in the patient’s journey to accessing innovative therapeutic options and should be accountable for progress.
- We aim to create compliant solutions that are designed to empower patients to feel confident throughout their treatment journey.
- We advocate for policies, technology and evidence to promote innovation and reduce the time for approved treatments to reach patients.
- We partner with others for the sake of science and the good of patients, committed to the continuous evolution that began before we launched the world’s first RNAi therapeutic and will endure for as long as we are Alnylam.
50+
patient-reported outcome measures in clinical trials
185+
medical societies engaged
85+
patient advocacy organizations engaged in Alnylam’s network globally
190+
patient advocacy events supported worldwide
125k+
samples genotyped through Alnylam Act® or GeneActTM since the programs began
~1,400
patients participating in registries
You will be redirected to an external site that may include social media, event registration, or other third-party content related to Alnylam.
Please note that these external sites have their own terms of service and privacy policies, which may differ from those of Alnylam.
Proceed to Site